Wednesday, November 22, 2017 10:15 PM ET
G1 Therapeutics (GTHX) Insider Makes Significant Share Sale Slowing Buy Trend over Last 90 Days
A filing with the SEC today revealed a substantial insider sale of G1 Therapeutics shares as — MedImmune Ventures, Inc., 10% Owner — sold 200,000 shares in the company having a market value of approximately $4,002,000. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the purchase of 250,000 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 50,000 shares and have averaged 225,000 shares per transaction over this time period.
During the last 90 days, the number of insider buy/sell trades at G1 Therapeutics is above the 272-company peer group average. Bio Therapeutic Drugs peer group saw 335 buy/sell trades during this period for an average of 1.2 transactions per company. The number of shares per buy/sell trade for G1 Therapeutics insiders was also higher. Within the peer group there were 37,220,290 shares purchased and 21,408,033 shares sold with company insiders having bought 76,759 shares on average.
Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data used in creating and writing this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.